Gad El-Karim Mohamed Adel, Hegazy Mohammed Saad, Maged Asser, Fawzy Sameh K, Abdelghani Rania
Armed Forces College of Medicine, Cairo, Egypt.
Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Lasers Med Sci. 2025 Feb 1;40(1):58. doi: 10.1007/s10103-025-04308-y.
In this study, we aimed to investigate the efficacy and safety of combined fractional carbon dioxide laser and topical timolol maleate 0.5% solution versus topical timolol maleate 0.5% solution alone in inflammatory acne. Thirty adult patients with inflammatory facial acne were randomized in this study. The patients received 3 biweekly sessions of fractional CO2 laser on one side of the face followed by topical timolol maleate ophthalmic solution 0.5% once daily for 7 days on both sides. Outcome was evaluated 2 weeks after the first session, 2 weeks after the last session, and 1 month after the last session by lesion count, erythema, hyperpigmentation, qualitative global scarring grading, and patients' satisfaction. Side effects were also evaluated. Trial registration (IRB No. 417, 30/10/2023). At 2 weeks after the first session, there were insignificant differences between both sides regarding lesion count, erythema, hyperpigmentation, and qualitative global scarring grading (p value = 0.8, 0.05, 0.7, 0.1 respectively). At 2 weeks after the last session, the erythema on the combined side was reduced by a mean of 0.2 ± 0.4 SD compared to timolol only side with significant difference between both sides (p value = 0.03), while there were insignificant differences between both sides regarding lesion count, hyperpigmentation, qualitative global scarring grading, and patients' satisfaction (p value = 0.1, 0.5, 0.8, 0.3 respectively). Recurrence was detected at one month after the last session. No side effects were reported. Combined fractional CO2 laser and topical timolol maleate 0.5% solution were significantly more effective than topical timolol maleate 0.5% solution alone in reduction of erythema of inflammatory facial acne in adolescent men with Fitzpatrick's skin type III-IV at 2 weeks after 3 biweekly sessions with insignificant differences between both sides regarding lesion count, hyperpigmentation, qualitative global scarring grading, and patients' satisfaction. Further and larger studies are still needed.
在本研究中,我们旨在探讨联合使用分次二氧化碳激光和0.5%马来酸噻吗洛尔滴眼液与单独使用0.5%马来酸噻吗洛尔滴眼液治疗炎性痤疮的疗效和安全性。30名患有炎性面部痤疮的成年患者参与了本研究。患者面部一侧接受3次每两周一次的分次二氧化碳激光治疗,然后双侧每天一次使用0.5%马来酸噻吗洛尔滴眼液,持续7天。在第一次治疗后2周、最后一次治疗后2周以及最后一次治疗后1个月,通过皮损计数、红斑、色素沉着、定性整体瘢痕分级和患者满意度来评估疗效。同时也评估了副作用。试验注册(IRB编号417,2023年10月30日)。在第一次治疗后2周,两侧在皮损计数、红斑、色素沉着和定性整体瘢痕分级方面无显著差异(p值分别为0.8、0.05、0.7、0.1)。在最后一次治疗后2周,联合治疗侧的红斑平均比仅使用噻吗洛尔侧减少了0.2±0.4标准差,两侧之间存在显著差异(p值 = 0.03),而在皮损计数、色素沉着、定性整体瘢痕分级和患者满意度方面两侧无显著差异(p值分别为0.1、0.5、0.8、0.3)。在最后一次治疗后1个月检测到复发情况。未报告有副作用。对于皮肤菲茨帕特里克分型为III - IV型的青春期男性炎性面部痤疮,在每两周进行3次治疗后2周,联合分次二氧化碳激光和0.5%马来酸噻吗洛尔滴眼液在减轻红斑方面明显比单独使用0.5%马来酸噻吗洛尔滴眼液更有效,在皮损计数、色素沉着、定性整体瘢痕分级和患者满意度方面两侧无显著差异。仍需要进一步的大规模研究。